Deep vein thrombosis, pulmonary embolism - dabigatran etexilate (treatment, prevention): evaluation report

Table of Contents:

  • 01_Pre-meeting briefing
  • 02_Evidence review group report
  • 03_Erratum-evidence review group report
  • 04_Company submission - Boehringer indelheim
  • 05_NICE clarification letter
  • 06_NICE letter of correction to clarification questions
  • 07_Company response to the NICE clarification letter
  • 08_Statement - British Cardiovascular Society
  • 09_Statement - Clinical Leads of Thrombosis
  • 10_Statement - LifeBlood: The Thrombosis Charity
  • 11_Statement - Royal College of Nursing
  • 12_Statement - Royal College of Pathologist & British Society for Haematology
  • 13_Clinical Statement - MacCallum
  • 14_Patient statement - Eaton

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 31 October 2014